156 related articles for article (PubMed ID: 36939557)
1. Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials.
Rahman R; Ventz S; Redd R; Cloughesy T; Alexander BM; Wen PY; Trippa L
Clin Cancer Res; 2023 Jun; 29(12):2194-2198. PubMed ID: 36939557
[TBL] [Abstract][Full Text] [Related]
2. Leveraging external data in the design and analysis of clinical trials in neuro-oncology.
Rahman R; Ventz S; McDunn J; Louv B; Reyes-Rivera I; Polley MC; Merchant F; Abrey LE; Allen JE; Aguilar LK; Aguilar-Cordova E; Arons D; Tanner K; Bagley S; Khasraw M; Cloughesy T; Wen PY; Alexander BM; Trippa L
Lancet Oncol; 2021 Oct; 22(10):e456-e465. PubMed ID: 34592195
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
7. An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry.
Le Tourneau C; Perret C; Hackshaw A; Blay JY; Nabholz C; Geissler J; Do T; von Meyenn M; Dienstmann R
JCO Precis Oncol; 2022 Jul; 6():e2200019. PubMed ID: 35939770
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide for high grade glioma.
Hart MG; Garside R; Rogers G; Stein K; Grant R
Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341
[TBL] [Abstract][Full Text] [Related]
10. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
[TBL] [Abstract][Full Text] [Related]
11. Leveraging external control data in the design and analysis of neuro-oncology trials: Pearls and perils.
Polley MC; Schwartz D; Karrison T; Dignam JJ
Neuro Oncol; 2024 May; 26(5):796-810. PubMed ID: 38254183
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
13. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
14. Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.
Panje CM; Putora PM; Hundsberger T; Hottinger AF; Roelcke U; Pesce G; Herrmann E; Matter-Walstra K
Swiss Med Wkly; 2019 Dec; 149():w20153. PubMed ID: 31800087
[TBL] [Abstract][Full Text] [Related]
15. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
McBain C; Lawrie TA; Rogozińska E; Kernohan A; Robinson T; Jefferies S
Cochrane Database Syst Rev; 2021 May; 5(1):CD013579. PubMed ID: 34559423
[TBL] [Abstract][Full Text] [Related]
16. Neuro-oncology practices in Australia: a Cooperative Group for Neuro-Oncology patterns of care study.
Chen JY; Hovey E; Rosenthal M; Livingstone A; Simes J
Asia Pac J Clin Oncol; 2014 Jun; 10(2):162-7. PubMed ID: 23714694
[TBL] [Abstract][Full Text] [Related]
17. Payer perceptions on the use of patient-reported outcomes in oncology decision making.
Oderda G; Brixner D; Biskupiak J; Burgoyne D; Arondekar B; Deal LS; Quek RG; Niyazov A
J Manag Care Spec Pharm; 2022 Feb; 28(2):188-195. PubMed ID: 34806908
[No Abstract] [Full Text] [Related]
18. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators.
Nduom EK; Gephart MH; Chheda MG; Suva ML; Amankulor N; Battiste JD; Campian JL; Dacey RG; Das S; Fecci PE; Hadjipanayis CG; Hoang KB; Jalali A; Orringer D; Patel AJ; Placantonakis D; Rodriguez A; Yang I; Yu JS; Zipfel GJ; Dunn GP; Leuthardt EC; Kim AH
Neurosurgery; 2021 Jun; 89(1):129-132. PubMed ID: 33862619
[TBL] [Abstract][Full Text] [Related]
20. The use of external control data for predictions and futility interim analyses in clinical trials.
Ventz S; Comment L; Louv B; Rahman R; Wen PY; Alexander BM; Trippa L
Neuro Oncol; 2022 Feb; 24(2):247-256. PubMed ID: 34106270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
